CD8 Antibody (53-6.7) - BSA Free


Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of lymph nodes by multiple staining.
Immunohistochemistry-Paraffin: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - CD8 alpha expression in mouse spleen tissue using anti-CD8 alpha antibody. Image from verified customer more
Immunocytochemistry/ Immunofluorescence: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of bone marrow tissue by single and multiple staining.
Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Staining of peripheral blood leukocytes.
Immunocytochemistry/ Immunofluorescence: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of immersion fixed splenocytes. Primary antibody was used at a dilution of 10 ug/mL and more
Immunohistochemistry: CD8 Antibody (53-6.7) [NBP1-49045] - Histopathological analysis of spinal cord in EAE mice. Representative spinal cord sections from wild-type (WT), Asic1-/- , and Asic2-/- mice at 45 days after more
Flow Cytometry: CD8 Antibody (53-6.7) - BSA Free [NBP1-49045] - Analysis of isolated mouse splenic CD8+ T cells using CD8 antibody (53-6.7) [Allophycocyanin] (NBP1-49045APC). Image from verified customer review.
Immunohistochemistry-Frozen: CD8 Antibody (53-6.7) [NBP1-49045] - CD8 alpha Antibody (53-6.7) [NBP1-49045] - Analysis of mosue spleen sections. CD8+ lymphocytes are marked by brown labeling of the cell surface.
Immunohistochemistry-Frozen: CD8 Antibody (53-6.7) [NBP1-49045] - Analysis of CD8+ T cells in allogeneic skin grafted onto a mouse.
Flow Cytometry: CD8 Antibody (53-6.7) [NBP1-49045] - Analysis of fixed murine splenocytes by multiple staining.

Product Details

Reactivity Mu, RtSpecies Glossary
Applications Flow, ICC/IF, IHC, IP, Cell Depl, CyTOF-ready, Func
BSA Free
1 mg/ml

Order Details

CD8 Antibody (53-6.7) - BSA Free Summary

This CD8 alpha antibody serves as an effective marker of cytotoxic T lymphocytes by binding to the CD8 co-receptor expressed on the cell surface of cytotoxic T cells, recognizing the topological domain of CD8 alpha. Because this CD8 antibody is made to the alpha chain it will recognize both the CD8 alpha - CD8 beta heterodimer, the most common form, as well as the CD8 alpha - CD8 alpha homodimer. The CD8A gene is also expressed in natural killer cells (NK cells), dendritic cells and cortical thymocytes making the CD8 alpha antibody a potential marker for these cells.
CD8 Antibody (53-6.7) was developed against mouse thymus or spleen.
Most thymocytes, T cell subset, some NK cells
IgG2a Kappa
Protein A or G purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.


  • Cell depletion
  • CyTOF-ready
  • Flow Cytometry 1:10 - 1:1000
  • Immunocytochemistry/Immunofluorescence 1:10-1:500. Use reported in scientific literature
  • Immunohistochemistry 1:10-1:500
  • Immunohistochemistry-Frozen 1:10-1:500
  • Immunohistochemistry-Paraffin 1:10-1:500
  • Immunoprecipitation 1:10 - 1:500. Use reported in scientific literature (PMID 24565643)
  • Inhibition of T Cell Function
Application Notes
Each lot of this CD8a antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining, the suggested use of this reagent is <0.25 ug/10^6 cells in 100 uL volume. It is recommended that the reagent be titrated for optimal performance for each application. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation, in vivo and in vitro cell depletion, inhibition of CD8 T cell proliferation, blocking of cytotoxicity, and immunohistochemical staining of both acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections.
Theoretical MW
27 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Reviewed Applications
Read 3 Reviews rated 3.7
NBP1-49045 in the following applications:

Read Publications using
NBP1-49045 in the following applications:

Packaging, Storage & Formulations

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
0.02% Sodium Azide
1 mg/ml
Protein A or G purified

Alternate Names for CD8 Antibody (53-6.7) - BSA Free

  • 53-6.7 CD8 Alpha
  • 53-6.7 CD8 Aplha
  • 53-6.7 CD8
  • 53-6.7 Clone
  • 53-6.7
  • CD_antigen: CD8a
  • CD8 Antibody
  • CD8 antigen, alpha polypeptide (p32)
  • CD8
  • CD8a molecule
  • CD8A
  • Cytotoxic T cell marker
  • Cytotoxic T lymphocyte marker
  • Leu2 T-lymphocyte antigen
  • LEU2
  • MAL
  • OKT8 T-cell antigen
  • p32
  • T cell co-receptor
  • T cell marker
  • T8 T-cell antigen
  • T-cell antigen Leu2
  • T-cell surface glycoprotein CD8 alpha chain
  • T-lymphocyte differentiation antigen T8/Leu-2


CD8, also known as Leu-2 or T8 in human and Lyt2 or Lyt3 in mouse, is a cell surface glycoprotein belonging to the immunoglobulin supergene family (1, 2). CD8 is expressed on cytotoxic T-lymphocytes (T-cells), most thymocytes, between 35-45% of peripheral blood lymphocytes, and a population of natural killer (NK) cells (1, 2). The CD8 molecule consists of disulfide-linked alpha (alpha) and beta (beta) chains that present on T-cells as either CD8alphaalpha homodimers or CD8alphabeta heterodimers (1, 3). Both alpha and beta chains consist of a signaling sequence, an extracellular Ig-like domain, a membrane proximal stalk region, a transmembrane domain, and a cytoplasmic tail (3). Human CD8alpha is processed as 235 amino acids (aa) in length with a theoretical molecular weight of ~26 kDa, while mouse CD8alpha is 247 aa and has a theoretical molecular weight of 27.5 kDa (4, 5). Functionally, CD8 acts as an antigen coreceptor on cytotoxic T-cells and interacts with the major histocompatibility complex (MHC) class I molecules on antigen presenting cells (APCs), mediating cell-cell interactions within the immune system. Conversely, CD4 molecules interact with antigens presented on MHC class II molecules and are activated to become helper T-cells (TH) (1,2). Interestingly, thymocytes can transiently express both CD4 and CD8 during the maturation process (2). Furthermore, the cytoplasmic tail of CD8 has a Lck (lymphocyte-specific protein tyrosine kinase) binding domain where Lck interacts with CD8, initiating a phosphorylation cascade that activates transcription factors and promotes T-cell activation (6). More specifically, CD8alphabeta functions as a T-cell co-receptor, while CD8alphaalpha promotes T-cell survival and differentiation (7).

Given its role in the immune system, CD8-deficiency in T-cells is a hallmark of many diseases and pathologies (8-10). Specifically, CD8+ T-cell deficiency is prevalent in chronic autoimmune diseases including multiple sclerosis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, type 1 diabetes mellitus, and Graves' disease (8). Furthermore, cancers or chronic infection can lead to CD8 T-cell exhaustion as the continual antigen presentation and inflammatory signals eventually cause the CD8+ T-cells to lose functionality (9, 10). However, animal models and clinical studies have suggested that T-cells are capable of being reinvigorated using inhibitory receptor blockade resulting in better disease outcomes and these exhausted T-cells may be a potential therapeutic target (9, 10).

Alternative names for CD8 includes CD antigen: CD8a, CD8 antigen, alpha polypeptide (p32), CD8a molecule, CD8A, Leu2 T-lymphocyte antigen, LEU2, MAL, OKT8 T-cell antigen, p32, T cell co-receptor, T8 T-cell antigen, T-cell antigen Leu2, T-cell surface glycoprotein CD8 alpha chain, and T-lymphocyte differentiation antigen T8/Leu-2.


1. Littman D. R. (1987). The structure of the CD4 and CD8 genes. Annual review of immunology.

2. Naeim F. (2008). Chapter 2- Principles of Immunophenotyping. Hematopathology.

3. Gao, G. F., & Jakobsen, B. K. (2000). Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor. Immunology today.

4. UniProt (P01732)

5. UniProt (P01731)

6. Kappes D. J. (2007). CD4 and CD8: hogging all the Lck. Immunity.

7. Gangadharan, D., & Cheroutre, H. (2004). The CD8 isoform CD8alphaalpha is not a functional homologue of the TCR co-receptor CD8alphabeta. Current opinion in immunology.

8. Pender M. P. (2012). CD8+ T-Cell Deficiency, Epstein-Barr Virus Infection, Vitamin D Deficiency, and Steps to Autoimmunity: A Unifying Hypothesis. Autoimmune diseases.

9. Kurachi M. (2019). CD8+ T cell exhaustion. Seminars in immunopathology.

10. Hashimoto, M., Kamphorst, A. O., Im, S. J., Kissick, H. T., Pillai, R. N., Ramalingam, S. S., Araki, K., & Ahmed, R. (2018). CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annual review of medicine.


This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Customers Who Viewed This Item Also Viewed...

Species: Ca, Hu, Mu, Po, Rb, Rt
Applications: Dual ISH-IHC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, Simple Western, WB
Species: Hu
Applications: BA
Species: Ca, Hu, Mu, Po
Applications: Flow, ICC/IF, IHC, IHC-Fr, IHC-P, KD
Species: Hu
Applications: BA
Species: Hu
Applications: CyTOF-ready, ELISA, Flow, ICC/IF, IHC, IHC-P, PA, WB
Species: Hu, Mu
Applications: Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP, WB
Species: Hu
Applications: BA
Species: Mu
Applications: ELISA
Species: Hu
Applications: ELISA
Species: Hu
Applications: ELISA, ICC/IF, S-ELISA, WB
Species: Hu, Mu, Rt
Applications: CyTOF-ready, Flow, Func, ICC/IF, IHC, IHC-Fr, IHC-P, IP, In vitro, In vivo, WB
Species: Rt
Applications: B/N, CyTOF-ready, EM, ELISA, Flow-IC, Flow, ICC/IF, IHC, IHC-Fr, IHC-P, IP
Species: Hu
Applications: AgAct, ICC, WB
Species: Hu
Applications: ELISA
Species: Bv, Eq, Hu, Mu, Po, Rt
Applications: ICC/IF, IHC, WB
Species: Hu
Applications: B/N, Flow, IHC, IHC-Fr, WB
Species: Hu, Mu
Applications: CyTOF-ready, Flow, ICC, KO, Simple Western, WB
Species: Hu, Mu
Applications: CyTOF-ready, Flow, ICC/IF, In vitro, WB

Publications for CD8 Antibody (NBP1-49045)(22)

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 5 applications: FLOW, ICC/IF, IF/IHC, IHC-Fr, IHC-P.

Filter By Application
All Applications
Filter By Species
All Species
Showing Publications 1 - 10 of 22. Show All 22 Publications.
Publications using NBP1-49045 Applications Species
Son S, Nam J, Kim AS et al. Induction of T-helper-17-cell-mediated anti-tumour immunity by pathogen-mimicking polymer nanoparticles Nature biomedical engineering 2022-12-23 [PMID: 36564626] (IHC-Fr, Mouse) IHC-Fr Mouse
Salman S, Meyers DJ, Wicks EE Et al. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy J Clin Invest 2022-05-02 [PMID: 35499076] (FLOW, Mouse)

Citation using the Alexa Fluor 488 version of this antibody.
FLOW Mouse
Reyes AF, Goldusky J, Bhimalli P et al. Tracking fluorescently labeled IL-15 and anti-PD-1 in the tumor microenvironment and draining lymph nodes Journal of immunological methods 2022-03-28 [PMID: 35358495] (IF/IHC, Mouse) IF/IHC Mouse
Jie X, Chen Y, Zhao Y et al. Targeting KDM4C enhances CD8+ T cell mediated antitumor immunity by activating chemokine CXCL10 transcription in lung cancer Journal for immunotherapy of cancer 2022-02-01 [PMID: 35121645] (IF/IHC, Mouse) IF/IHC Mouse
Zhang Z, Na H, Gan Q Et al. Monomeric C-reactive protein via endothelial CD31 for neurovascular inflammation in an ApoE genotype-dependent pattern: A risk factor for Alzheimer's disease? Aging cell 2021-10-23 [PMID: 34687487] (IHC-Fr, Mouse) IHC-Fr Mouse
Yang W, Feng Y, Zhou J et al. A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma Science translational medicine 2021-04-07 [PMID: 33827976]
Hoover AA, Hufnagel DH, Harris W et al. Lupeol Counteracts the Proinflammatory Signalling Triggered in Macrophages by 7-Keto-Cholesterol: New Perspectives in the Therapy of Atherosclerosis BMC Cancer 2020-09-27 [PMID: 33028251] (IHC-P, Mouse) IHC-P Mouse
Samanta D, Huang T, Shah R et al. BIRC2 Expression Impairs Anti-Cancer Immunity and Immunotherapy Efficacy Cell Rep [PMID: 32846130] (FLOW, Mouse)

Citation using the PE format of this antibody.
FLOW Mouse
Westrich JA, Vermeer DW, Silva A et al. CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8+ T-cell responses by upregulating MHC-I expression Oncogene 2019-08-15 [PMID: 31417179] (ICC/IF, Mouse) ICC/IF Mouse
Fazia T, Pastorino R, Notartomaso S et al. Acid Sensing Ion Channel 2: a new potential player in the pathophysiology of multiple sclerosis Eur. J. Neurosci. 2018-12-14 [PMID: 30549327] (IF/IHC, Mouse) IF/IHC Mouse
Show All 22 Publications.

Reviews for CD8 Antibody (NBP1-49045) (3) 3.73

Average Rating: 3.7
(Based on 3 reviews)
We have 3 reviews tested in 1 species: Mouse.

Reviews using NBP1-49045:
Filter by Applications
All Applications
Filter by Species
All Species
Images Ratings Applications Species Date Details
Immunohistochemistry-Paraffin CD8 NBP1-49045
reviewed by:
Verified Customer
IHC-P Mouse 03/02/2021


Sample TestedFFPE mouse liver


CommentsAttempted IF with this primary antibody against CD8 at concentrations 1:500, 1:200, 1:100, 1:50, 1:20, and 1:10. At concentrations >1:100 we were able to see dim positivity for IHC with HRP, but we were never able to visualize CD8 cells with immunofluorescence using either Alexa 488 and Alexa 468 secondaries (both secondaries confirmed working against other rat primaries). Unfortunately we needed to costain against two other targets so IHC alone didn't work for our purposes.
***Novus Response: Thank you for reviewing our product. We are sorry to that that this antibody did not perform as expected. We have been in touch with the customer to resolve this issue according to our Product Guarantee and to the customer’s satisfaction.***
Immunohistochemistry-Paraffin CD8 NBP1-49045
reviewed by:
weiwei deng
IHC-P Mouse 10/23/2017


Sample Testedmouse Head and neck squamous cell carcinoma (HNSCC)


Commentssections were incubated with antibody for CD8 alpha (Novus, 1:200, for mouse HNSCC samples) at 4 °C for 12 h.
Immunohistochemistry-Paraffin CD8 NBP1-49045
reviewed by:
Verified Customer
IHC-P Mouse 12/15/2014


Sample TestedMouse Spleen

Product General Protocols

Video Protocols

ICC/IF Video Protocol

FAQs for CD8 Antibody (NBP1-49045). (Showing 1 - 1 of 1 FAQs).

  1. Could you provide me with any suggestions for CD8 antibodies that work well with a CD4 antibody?
    • NBP1-28254, NBP1-28336, NBP1-28238, NBP1-49045 and NBP2-80658 have images of mostly Flow Cytometry analyses for CD4 and CD8. NB200-578 induces transplantation tolerance when used in conjunction with CD4 antibodies. I would suggest taking a look at these products to determine if they would be suitable for your experiments.

Secondary Antibodies


Isotype Controls

Additional CD8 Products

Bioinformatics Tool for CD8 Antibody (NBP1-49045)

Discover related pathways, diseases and genes to CD8 Antibody (NBP1-49045). Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Visit Tool

Diseases for CD8 Antibody (NBP1-49045)

Discover more about diseases related to CD8 Antibody (NBP1-49045).

Pathways for CD8 Antibody (NBP1-49045)

View related products by pathway.

PTMs for CD8 Antibody (NBP1-49045)

Learn more about PTMs related to CD8 Antibody (NBP1-49045).

Research Areas for CD8 Antibody (NBP1-49045)

Find related products by research area.

Blogs on CD8. Showing 1-10 of 13 blog posts - Show all blog posts.

Is Monkeypox Still A Threat?
By Jamshed Arslan, Pharm D, PhD Monkeypox is not deadly like its cousin, smallpox, nor is it as contagious as COVID-19. Yet, it continues to scare the world. In May 2022, a multinational outbreak of a cont...  Read full blog post.

Tired T cells: Hypoxia Drives T cell Exhaustion in the Tumor Microenvironment
By Hunter MartinezThe paradigm shifting view of the immune system being leveraged to target cancer has led to numerous therapeutic breakthroughs. One major cell group responsible for this revelation is a T cell. ...  Read full blog post.

Synthetic Biotic Medicine as Immunotherapy Against Cancer: Evidence From Arginine-Producing Engineered Bacteria
By Jamshed Arslan, Pharm D, PhDWhat do nuts, dairy and red meat have in common? In addition to the fact that they are all edible, one of the answers is L-arginine. This amino acid improves T cell’s respons...  Read full blog post.

Harnessing Natural Killer Cell Activity for Anti-Tumor Immunotherapy
By Victoria Osinski, PhDWhat’s “Natural” About Natural Killer (NK) Cells?For immunologists, the term cytotoxicity often conjures up images of an army of antigen specific CD8+ T cells deploying to ...  Read full blog post.

Early T cell response is associated with mild COVID-19 and rapid SARS-CoV-2 clearance
Jamshed Arslan, Pharm D, PhD SARS-CoV-2 induces both humoral and cellular immunity. A vaccine or natural infection invokes SARS-CoV-2-specific humoral components (antibodies from activated B cells) and cellular resp...  Read full blog post.

  Read full blog post.

Success of combined IL-10 and IL-12 therapy in colon cancer depends on IFN-gamma and gut barrier integrity
By Jamshed Arslan, Pharm. D., PhD. Colon cancer is responsible for over 600,000 deaths per year worldwide. Colon cancer can be classified into two categories: mismatch repair (MMR)-deficient and MMR-proficient cancers...  Read full blog post.

mTOR Signaling and the Tumor Microenvironment
By Yoskaly Lazo-Fernandez, PhD The mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase that, as a member of two distinct intracellular protein complexes, mTORC1 and mTORC2, regulates protein ...  Read full blog post.

The role of MHC Class II RT1B and immune response post brain injury
The major histocompatibility complex (MHC) is responsible for binding peptide fragments arising from pathogens in order to display them on the cell surface for recognition from immune cells.  Once recognized, the foreign pathogen is typically evade...  Read full blog post.

Topics in CD11b: The innate immune response
Integrins are transmembrane receptors composed of alpha and beta chains, where beta-integrins are mainly expressed in leukocytes. Leukocytes are white blood cells that act in the immune system to defend our body against foreign pathogens.  Integrin...  Read full blog post.

Showing 1-10 of 13 blog posts - Show all blog posts.
mFlour Violet Conjugated Antibodies

Contact Information

Product PDFs


Concentration Calculator

The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.


Recent Reviews


Verified Customer
Application: IHC-P
Species: Mouse

weiwei deng
Application: IHC-P
Species: Mouse

Verified Customer
Application: IHC-P
Species: Mouse


Gene Symbol CD8A